Literature DB >> 18081894

Endothelial hyperplasia and endothelial galectin-3 expression are prognostic factors in primary central nervous system lymphomas.

Nicky D'Haene1, Xavier Catteau, Calliope Maris, Benoit Martin, Isabelle Salmon, Christine Decaestecker.   

Abstract

Recently, considerable attention has been focused on the identification of clinically relevant prognostic markers for primary central nervous system lymphomas (PCNSL). The present study investigated whether three morphological features, i.e. necrosis, reactive perivascular T-cell infiltrate and endothelial hyperplasia, and galectin-1 and galectin-3 immunohistochemical expression have prognostic roles in a series of 58 PCNSL samples from 44 immunocompetent and 14 immunocompromised patients. The presence of endothelial hyperplasia (identified in 21% of the assessable cases) was identified as a bad prognostic factor for immunocompetent PCNSL patients, whereas the other morphological features were not associated with any prognostic value. Lymphomatous cells of eight PCNSL cases expressed galectin-3 without any prognostic value, and lymphomatous cells did not express galectin-1. In contrast, endothelial expression of galectin-3 was identified (by means of uni- and multi-variate analyses) as a bad prognostic factor for immunocompetent PCNSL patients. In addition, a combination of endothelial hyperplasia and/or endothelial galectin-3 expression was shown to be an independent prognostic factor for immunocompetent PCNSL patients treated with methotrexate-based chemotherapy. In summary, this study suggests that endothelial-related markers can identify risk groups of PCNSL patients and indicates that galectin-3 could be involved in PCNSL angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18081894     DOI: 10.1111/j.1365-2141.2007.06929.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

1.  Prognostic impact of MYC protein expression in central nervous system diffuse large B-cell lymphoma: comparison with MYC rearrangement and MYC mRNA expression.

Authors:  Seung-Myoung Son; Sang-Yun Ha; Hae-Yong Yoo; Dongryul Oh; Seok-Jin Kim; Won-Seog Kim; Young-Hyeh Ko
Journal:  Mod Pathol       Date:  2016-09-30       Impact factor: 7.842

Review 2.  Galectins in tumor angiogenesis.

Authors:  Arjan W Griffioen; Victor L Thijssen
Journal:  Ann Transl Med       Date:  2014-09

Review 3.  Galectin-3 in angiogenesis and metastasis.

Authors:  Tatsuyoshi Funasaka; Avraham Raz; Pratima Nangia-Makker
Journal:  Glycobiology       Date:  2014-08-18       Impact factor: 4.313

Review 4.  Galectin Family Members: Emerging Novel Targets for Lymphoma Therapy?

Authors:  Yuanwei Shi; Danting Tang; Xiaoqi Li; Xiaoli Xie; Yufu Ye; Lijuan Wang
Journal:  Front Oncol       Date:  2022-05-23       Impact factor: 5.738

5.  New developments in the pathology of malignant lymphoma: a review of the literature published from January to April 2008.

Authors:  J Han J M van Krieken
Journal:  J Hematop       Date:  2008-07       Impact factor: 0.196

6.  Prognostic significance of the aggregative perivascular growth pattern of tumor cells in primary central nervous system diffuse large B-cell lymphoma.

Authors:  Miaoxia He; Changjing Zuo; Jianjun Wang; Jianmin Liu; Binghua Jiao; Jianmin Zheng; Zailong Cai
Journal:  Neuro Oncol       Date:  2013-03-12       Impact factor: 12.300

7.  MR perfusion in and around the contrast-enhancement of primary CNS lymphomas.

Authors:  Stella Blasel; Alina Jurcoane; Oliver Bähr; Lutz Weise; Patrick N Harter; Elke Hattingen
Journal:  J Neurooncol       Date:  2013-05-22       Impact factor: 4.130

8.  VEGFR1 and VEGFR2 involvement in extracellular galectin-1- and galectin-3-induced angiogenesis.

Authors:  Nicky D'Haene; Sébastien Sauvage; Calliope Maris; Ivan Adanja; Marie Le Mercier; Christine Decaestecker; Linda Baum; Isabelle Salmon
Journal:  PLoS One       Date:  2013-06-17       Impact factor: 3.240

9.  MYC protein expression in primary diffuse large B-cell lymphoma of the central nervous system.

Authors:  Kamraan Z Gill; Fabio Iwamoto; Ashleigh Allen; Daniela Hoehn; Vundavalli V Murty; Bachir Alobeid; Govind Bhagat
Journal:  PLoS One       Date:  2014-12-05       Impact factor: 3.240

10.  Risk Prediction for Early Mortality in Patients with Newly Diagnosed Primary CNS Lymphoma.

Authors:  Chia-Hsin Lin; Ching-Fen Yang; Huai-Che Yang; Li-Yu Fay; Chiu-Mei Yeh; Ai-Seon Kuan; Hao-Yuan Wang; Jyh-Pyng Gau; Liang-Tsai Hsiao; Tzeon-Jye Chiou; Po-Min Chen; Yao-Chung Liu; Po-Shen Ko; Jin-Hwang Liu; Chia-Jen Liu
Journal:  J Cancer       Date:  2019-07-05       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.